Mikhail Eydelman

Senior Vice President, General Counsel and Corporate SecretaryatVaxcyte· In proxies 2022–2025

Pay in FY2024+62% from the year before · Vaxcyte stock +30.4% the same year

Mikhail Eydelman was paid $5.7M in FY2024 (Dec), up 62%. Vaxcyte stock rose 30.4% that year.

Pay$100 in the stock at the end of FY21 → $344

Pay is from the Summary Compensation Table of each Vaxcyte proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

PCVX
VaxcytePublic company · 4 yr
- Senior Vice President, General Counsel and Corporate Secretary2022 – Present · 4 yrStock in role +166%

Roles come from the proxy statements of each company.

Activity

Pay
Vaxcyte General counsel pay rose 62% to $5.7M. The stock rose 30% in FY2024 (Dec).
DEF 14AApr 28, 2025
Pay
Vaxcyte General counsel pay fell 30% to $3.5M. The stock rose 31% in FY2023 (Dec).
DEF 14AApr 15, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?